Market Cap
$126.1M
INO
INOVIO PHARMACEUTICALS, INC.
$1.18 ▼ -2.07%
Prev close $1.21Market cap$126.1M
ConsensusBuy
12-mo target$3.17 (+167.2%)
▲ Bullish
Analyst conviction 8/10
10 New Institutional Positions6 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on INO right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (75%)
Inst. Holders
50 funds
Inst. Value
$31.3M
Inst. Activity
10 buys / 6 sells
Social Sentiment
45° Neutral
SEC Reports
7
Press Releases
1
Price chart 30d -12.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 30, 2026 fda_pdufa
Jul 31, 2026 SEC PDUFA: INO — INO-3107 in Recurrent Respiratory Papillomatosis (RRP) — 2026-10-30
FDA target action date 2026-10-30 for INO (INOVIO PHARMACEUTICALS, INC.). Drug: INO-3107. Indication
Inovio Pharmaceuticals priced a $20M public offering of 21M shares and warrants for 42M shares (or pre-funded warrants)
8-K — Impact 6/10
Inovio Pharmaceuticals (INO) is raising ~$18.3M net via a 424B5 takedown from its $300M shelf, selling 21.1M shares and
424B5 — Impact 6/10
Inovio Pharmaceuticals priced a $20M underwritten public offering of 21,052,632 shares and warrants to purchase up to 42
Impact 7/10
Inovio Pharmaceuticals' universal shelf registration (S-3) filed July 2, 2026 has become effective, allowing the company
EFFECT — Impact 6/10
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — ADD
3,650,562 shares ($4.0M)
Jun 30, 2026 Inst.
D. E. Shaw & — TRIM
1,351,656 shares ($1.5M)
May 20, 2026 Insider
Sumner Michael John surrendered for taxes 2,693 shares
Chief Medical Officer @ $1.23 ($3.3K)
Analyst ratings buy % +7.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
75% rate it Buy or better · 8 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 13, 2026 | Jefferies | UPGRADE | Buy | 53% |
| Aug 3, 2026 | Piper Sandler | REITERATE | Overweight | 54% |
| Jun 1, 2026 | HC Wainwright & Co. | MAINTAIN | Neutral | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Aug 1, 2026 | 1 | 4 | 3 | 0 | 0 | 63% | |
| Jul 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| Jun 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% | |
| May 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% | |
| Apr 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% | |
| Mar 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% | |
| Feb 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% |
Price targets
Where 3 covering analysts think INO trades over the next 12 months.
$3.17 +167.2% upside Strong Buy
Current$1.19 Low$2.50 Median$3.00 High$4.00 3 analysts
$2.50$4.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
45°
Neutral
BearishNeutralBullish
Recent posts
30 JULY 2026 , WHAT ARE THE BIGGEST LOSERS AND WHY ?
▲ 1 · 💬 1· ⚡ 0.5
Today’s Momentum Watchlist - Volume First, Entries Second
▲ 1 · 💬 1· ⚡ 0.5
A few small caps I’m watching into the session
▲ 1 · 💬 1· ⚡ 0.5
HANTAVIRUS - Potential?
▲ 1 · 💬 0· ⚡ 0.2
Why is Inovio Board investing in the Co. even as shares crash? It's a tell to a card player- A strong future movement is in the cards?
▲ 1 · 💬 0· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
7 SEC filing reports analyzed · 0 bullish, 6 bearish, 0 mixed, 1 neutral · avg impact 5.6/10.Plus 1 press releases.
BEARISH8-K6/10
Inovio Pharmaceuticals priced a $20M public offering of 21M shares and warrants for 42M shares (or p
Jul 31, 2026
BEARISH424B56/10
Inovio Pharmaceuticals (INO) is raising ~$18.3M net via a 424B5 takedown from its $300M shelf, selli
Jul 30, 2026
BEARISHEFFECT6/10
Inovio Pharmaceuticals' universal shelf registration (S-3) filed July 2, 2026 has become effective,
Jul 13, 2026
BEARISHS-36/10
Inovio Pharmaceuticals (INO) filed a universal shelf registration statement on Form S-3 on July 2, 2
Jul 2, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 30, 2026
fda_pdufa
PDUFA: INO — INO-3107 in Recurrent Respiratory Papillomatosis (RRP) — 2026-10-30
FDA target action date 2026-10-30 for INO (INOVIO PHARMACEUTICALS, INC.). Drug: INO-3107. Indication: Recurrent Respiratory Papillomatosis (RRP). FDA
Oct 2, 2026
Clinical Trial
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Oct 2, 2026
clinical_trial_readout
T-90d Trial Readout: INO-5401 (Phase 2)
Trial: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) Sponsor
Sep 8, 2026
Clinical Trial
INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Phase Phase 2 — COMPLETED
Sep 1, 2026
other
INOVIO to Participate in Upcoming Investor Conferences
PLYMOUTH MEETING, Pa., Sept. 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medici
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.20 | $-0.20–$-0.19 | 77.6% | +20.9% | 2↑ 0↓ | $0.0B | 2 |
| Next Q | $-0.18 | $-0.18–$-0.18 | 35.1% | -12.5% | 2↑ 0↓ | $0.0B | 2 |
| Current FY | $-0.73 | $-0.73–$-0.73 | 59.9% | +36.0% | 1↑ 0↓ | $0.0B | 1 |
| Next FY | $-0.44 | $-0.67–$-0.21 | 39.7% | -7.3% | 2↑ 0↓ | $0.1B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.195 | — |
| 7d ago | $-0.235 | +0.040 |
| 30d ago | $-0.247 | +0.052 |
| 60d ago | $-0.247 | +0.052 |
| 90d ago | $-0.242 | +0.047 |
Institutional ownership
Which big funds own INO (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $31.3M total value (28,564,668 shares) as of 2026-Q2. Top holders: FMR, Jupiter, VANGUARD. Net buying activity: 10 institutions added/increased vs 6 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 8,454,797 | $9.3M | 29.7% | DOUBLED +756753.5% |
| Jupiter Topco LLC | 5,171,053 | $5.7M | 18.3% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,650,562 | $4.0M | 12.8% | ADD +25.8% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,520,400 | $1.7M | 5.3% | — |
| D. E. Shaw & Co., Inc. | 1,351,656 | $1.5M | 4.8% | TRIM -38.9% |
| TWO SIGMA INVESTMENTS, LP | 1,239,778 | $1.4M | 4.4% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 802,751 | $883.7K | 2.8% | ADD +40.7% |
| MILLENNIUM MANAGEMENT LLC | 796,107 | $875.7K | 2.8% | TRIM -43.6% |
| BlackRock, Inc. | 779,057 | $857.0K | 2.7% | — |
| VANGUARD FIDUCIARY TRUST CO | 480,769 | $528.8K | 1.7% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | 2,901,208 | 3,650,562 | +25.8% | $4.0M |
| D. E. Shaw & Co., Inc. | TRIM | 2,212,819 | 1,351,656 | -38.9% | $1.5M |
| MILLENNIUM MANAGEMENT LLC | TRIM | 1,410,845 | 796,107 | -43.6% | $875.7K |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 643,777 | 361,339 | -43.9% | $397.5K |
| NORTHERN TRUST CORP | TRIM | 298,870 | 174,394 | -41.6% | $191.8K |
| JANE STREET GROUP, LLC | DOUBLED | 30,691 | 124,525 | +305.7% | $137.0K |
| GOLDMAN SACHS GROUP INC | DOUBLED | 44,724 | 93,720 | +109.6% | $103.1K |
| RAYMOND JAMES FINANCIAL INC | DOUBLED | 16,543 | 42,286 | +155.6% | $46.5K |
| Squarepoint Ops LLC | ADD | 24,837 | 36,391 | +46.5% | $40.0K |
| BARCLAYS PLC | DOUBLED | 506 | 3,487 | +589.1% | $3.8K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
11 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 20, 2026 | Sumner Michael John | Chief Medical Officer | TAX W/H | 2,693 | $1.23 | $3.3K |
| May 20, 2026 | Sumner Michael John | Chief Medical Officer | EXERCISE | 9,450 | — | — |
| May 20, 2026 | Sumner Michael John | Chief Medical Officer | AWARD | 46,876 | — | — |
| May 20, 2026 | Sumner Michael John | Chief Medical Officer | AWARD | 37,684 | — | — |
| May 20, 2026 | Humeau Laurent | Chief Scientific Officer | EXERCISE | 6,027 | — | — |
| May 20, 2026 | Humeau Laurent | Chief Scientific Officer | TAX W/H | 2,163 | $1.23 | $2.7K |
| May 20, 2026 | Humeau Laurent | Chief Scientific Officer | AWARD | 34,160 | — | — |
| May 20, 2026 | Humeau Laurent | Chief Scientific Officer | AWARD | 27,440 | — | — |
| May 20, 2026 | DANSEY ROGER D | Director | AWARD | 34,200 | — | — |
| May 20, 2026 | BENITO SIMON X | Director | AWARD | 41,800 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for INO.
Shares short
19,921,776
Settlement Sep 15, 2026
Change vs prior
+3.5%
Semi-monthly cycle
Days to cover
6.5
At avg daily volume
Of shares outstanding
≈19.3%
Estimate — not % of float
All INO filing & press-release reports (8)
- 8-K reportJul 31, 2026
- 424B5 reportJul 30, 2026
- PRESS-RELEASE reportJul 30, 2026
- EFFECT reportJul 13, 2026
- S-3 reportJul 2, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportApr 6, 2026
- 424B5 reportApr 2, 2026